These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28939742)

  • 41. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
    Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
    J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
    Hardy LR; Pergande MR; Esparza K; Heath KN; Önyüksel H; Cologna SM; Burdette JE
    Oncogene; 2019 Aug; 38(32):6003-6016. PubMed ID: 31296958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
    Zhan F; Guo Y; He L
    J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
    Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
    Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia: a study of single institution in Japan.
    Munakata S; Yamamoto T
    Int J Gynecol Pathol; 2015 Jan; 34(1):9-18. PubMed ID: 25473747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucins and Truncated
    Coelho R; Marcos-Silva L; Mendes N; Pereira D; Brito C; Jacob F; Steentoft C; Mandel U; Clausen H; David L; Ricardo S
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011875
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutant p53 expression in fallopian tube epithelium drives cell migration.
    Quartuccio SM; Karthikeyan S; Eddie SL; Lantvit DD; Ó hAinmhire E; Modi DA; Wei JJ; Burdette JE
    Int J Cancer; 2015 Oct; 137(7):1528-38. PubMed ID: 25810107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of growth hormone secretagogue receptor type 1a, the functional ghrelin receptor, in human ovarian surface epithelium, mullerian duct derivatives, and ovarian tumors.
    Gaytan F; Morales C; Barreiro ML; Jeffery P; Chopin LK; Herington AC; Casanueva FF; Aguilar E; Dieguez C; Tena-Sempere M
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1798-804. PubMed ID: 15585554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma.
    Gurler H; Macias V; Kajdacsy-Balla AA; Barbolina MV
    Biomolecules; 2015 Dec; 5(4):3438-47. PubMed ID: 26633537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues.
    Brandenberger AW; Tee MK; Jaffe RB
    J Clin Endocrinol Metab; 1998 Mar; 83(3):1025-8. PubMed ID: 9506768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    Veskimäe K; Staff S; Tabaro F; Nykter M; Isola J; Mäenpää J
    Genes Chromosomes Cancer; 2015 May; 54(5):276-87. PubMed ID: 25706666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
    Russo A; Czarnecki AA; Dean M; Modi DA; Lantvit DD; Hardy L; Baligod S; Davis DA; Wei JJ; Burdette JE
    Oncogene; 2018 Apr; 37(15):1976-1990. PubMed ID: 29367766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.
    Nishida N; Murakami F; Higaki K
    Pathol Int; 2016 Jun; 66(6):337-42. PubMed ID: 27250113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
    Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
    Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
    Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
    Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
    Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.